CDMO Ritedose Corporation announced that it has added blow-fill-seal (BFS) capacity to its manufacturing facility in Columbia, SC, USA that will allow it to manufacture an additional 180 million unit doses of opthalmic and respiratory solutions. In addition to contract development and manufacturing, Ritedose manufactures its own generic inhalation solutions, including albuterol sulfate, ipatropium bromide, arformoterol tartrate, and cromolyn sodium. The company said that the new capacity is expected to come on line in August 2024.
Ritedose CEO Jody Chastain commented, “Ritedose has co-developed and commercialized more than 80% of new products introduced in a BFS dosage form for the past 10 years. This track record of successful partnerships highlights the company’s role as a key innovator in the BFS sector and a trusted collaborator for pharmaceutical companies. To remain laser focused on growing our capacity, innovation and specialty in BFS, we are making a strategic decision to pivot the necessary resources away from our 503B Outsourcing Division, concentrating all resources to FDA approved drug products,”
Read the Ritedose press release.
